• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

    18.34 +0.55 (+3.09%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 859,713
    Open 18.30
    Bid (Size) 18.10 (100)
    Ask (Size) 18.50 (400)
    Prev. Close 17.79
    Today's Range 18.13 - 18.57
    52wk Range 5.950 - 62.75
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? ↗
    Focused on novel immunotherapies for inflammatory diseases, this biotech firm reported significant insider selling in its latest filing. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares ↗
    Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for the stock. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +53.5%
    +53.5%
    1 Month
    +10.0%
    +10.0%
    3 Month
    +12.3%
    +12.3%
    6 Month
    +96.0%
    +96.0%
    1 Year
    -54.1%
    -54.1%

    More News

    Read More
    News headline image
    This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations ↗
    Via Stocktwits
    News headline image
    Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗
    Via The Motley Fool
    News headline image
    Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics Artificial Intelligence ETFs Government
    News headline image
    MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown ↗
    Via Stocktwits
    News headline image
    MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week ↗
    Via Stocktwits
    News headline image
    Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Minutes: Why NVDA, TSLA, AAPL, APLD, PANW Are On Traders' Radar Today ↗
    Via Stocktwits
    Topics ETFs Economy Lawsuit
    News headline image
    MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗
    Via Stocktwits
    News headline image
    MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event ↗
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
    From ImageneBio, Inc.
    Via GlobeNewswire
    News headline image
    BioTech Breakout: MoonLake Up 30% On FDA Wins ↗
    Via MarketBeat
    News headline image
    MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab ↗
    Via Stocktwits
    News headline image
    MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
    Via MarketMinute
    Topics Intellectual Property
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗
    Via Stocktwits
    Get insights into the top gainers and losers of Thursday's pre-market session. ↗
    Via Chartmill
    News headline image
    MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
    From DJS Law Group
    Via Business Wire
    News headline image
    MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th
    From Bragar Eagel & Squire
    Via GlobeNewswire

    Frequently Asked Questions

    Is MoonLake Immunotherapeutics - Class A Ordinary Shares publicly traded?
    Yes, MoonLake Immunotherapeutics - Class A Ordinary Shares is publicly traded.
    What exchange does MoonLake Immunotherapeutics - Class A Ordinary Shares trade on?
    MoonLake Immunotherapeutics - Class A Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares?
    The ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares is MLTX on the Nasdaq Stock Market
    What is the current price of MoonLake Immunotherapeutics - Class A Ordinary Shares?
    The current price of MoonLake Immunotherapeutics - Class A Ordinary Shares is 18.34
    When was MoonLake Immunotherapeutics - Class A Ordinary Shares last traded?
    The last trade of MoonLake Immunotherapeutics - Class A Ordinary Shares was at 04/17/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.